Department of Internal Medicine, School of Medicine, Kangwon National University, 1 Kangwondaehakgil, Chuncheon, Gangwon-do, 24431, South Korea.
Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, 04763, South Korea.
Stem Cell Res Ther. 2022 Sep 2;13(1):433. doi: 10.1186/s13287-022-03136-z.
Pulmonary fibrosis (PF) is a fatal chronic disease characterized by accumulation of extracellular matrix and thickening of the alveolar wall, ultimately leading to respiratory failure. PF is thought to be initiated by the dysfunction and aberrant activation of a variety of cell types in the lung. In particular, several studies have demonstrated that macrophages play a pivotal role in the development and progression of PF through secretion of inflammatory cytokines, growth factors, and chemokines, suggesting that they could be an alternative therapeutic source as well as therapeutic target for PF. In this review, we describe the characteristics, functions, and origins of subsets of macrophages involved in PF and summarize current data on the generation and therapeutic application of macrophages derived from pluripotent stem cells for the treatment of fibrotic diseases. Additionally, we discuss the use of macrophage-derived exosomes to repair fibrotic lung tissue.
肺纤维化(PF)是一种致命的慢性疾病,其特征是细胞外基质的积累和肺泡壁的增厚,最终导致呼吸衰竭。PF 被认为是由肺部各种细胞类型的功能障碍和异常激活引发的。特别是,有几项研究表明,巨噬细胞通过分泌炎症细胞因子、生长因子和趋化因子,在 PF 的发展和进展中发挥关键作用,这表明它们可能是 PF 的另一种治疗来源和治疗靶点。在这篇综述中,我们描述了参与 PF 的巨噬细胞亚群的特征、功能和来源,并总结了目前关于多能干细胞衍生的巨噬细胞的生成和治疗应用的数据,以治疗纤维化疾病。此外,我们还讨论了利用巨噬细胞衍生的外泌体来修复纤维化的肺组织。